omalizumab
Sign in to saveAlso known as IGE025, Ig gamma-1 chain C region, IGE25, Olizumab, RG-3648, Rhumab-E25
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458283563
- Drug.type
- mab
- Drug.image
- Omalizumab.png
- Drug.caption
- Omalizumab structure: (A) murine complementarity-determining region and (B) IgG1κ human framework
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- IgE Fc region
- Drug.tradename
- Xolair
- Drug.MedlinePlus
- a603031
- Drug.DailyMedID
- Omalizumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- R03
- Drug.ATC_suffix
- DX05
- Drug.biosimilars
- Omalizumab-igec, Omlyclo
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Research
4,813 papers- Omalizumab safety concerns.The Journal of allergy and clinical immunology · 2025
- A practical guide for implementing omalizumab therapy for food allergy.The Journal of allergy and clinical immunology · 2024
- Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.Clinical reviews in allergy & immunology · 2020
- Omalizumab for food allergy.Current opinion in allergy and clinical immunology · 2025
- Omalizumab and other biologics in drug desensitization.Current opinion in allergy and clinical immunology · 2020
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Has use
- medication
Show 7 more facts
- medical condition treated
- urticaria
- World Health Organisation international non-proprietary name
- omalizumab
- defined daily dose
- 16.0
- subject has role
- monoclonal antibody
- Commons category
- Omalizumab
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~16 min read
Encyclopedic overview
16 sectionsContents
- Medical uses
- Allergic asthma
- Chronic spontaneous urticaria
- Food allergy
- Chemistry and formulations
- Mechanism of action
- IgE in allergic diseases
- Roles in non-allergic diseases
- Adverse effects
- History
- Society and culture
- Legal status
- Biosimilars
- Economics
- See also
- References
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.
Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.
Excerpted from Wikipedia’s “omalizumab” article, available under the CC BY-SA 4.0 licence.